Introduction {#sec111}
============

Advances in percutaneous coronary intervention (PCI) techniques, improvement in coronary stent designs, and more effective antithrombotic therapies have made coronary stent thrombosis a rare complication. The incidence at 30 days is \<1%, whereas rates of late and very late stent thrombosis are 0.5% to 1% and 0.2% to 2% per year, respectively ([@bib1]). Coronavirus disease-2019 (COVID-19) has modified the usual presentation of many diseases as we know them. This disease promotes a sustained prothrombotic state, triggered by interactions among proinflammatory cytokines, procoagulant factors, and platelets. We have recently observed an increase in stent thrombosis during the COVID-19 pandemic peak in our center, the Complejo Hospitalario Universitario de Albacete in Albacete, Spain.Learning Objectives•COVID-19 increases both arterial and venous thrombogenicity.•The SARS-CoV-2 hypercoagulable state may lead to a stent thrombosis trigger in the presence of other mechanical and biological risk factors.•Recommendations on antithrombotic treatment and PCI for acute coronary syndromes should be maintained during COVID-19 treatment.

Case Reports {#sec1}
============

Case 1 {#sec1.1}
------

A 49-year-old man underwent primary angioplasty for a lateral ST-segment elevation myocardial infarction (STEMI) 6 h after the onset of symptoms ([Figures 1A to 1F](#fig1){ref-type="fig"} ). Balloon angioplasty in a small ramus intermedius was performed. To decrease hospital length of stay, ad hoc PCI was performed in the circumflex artery with 2 overlapped drug-eluting stents (DES) ([Videos 1](http://jacccr.acc.org/video/2020/20_1411_VID1.mp4){#intref0015} and [2](http://jacccr.acc.org/video/2020/20_1411_VID2.mp4){#intref0020}). Thirty minutes later, there was new onset of more intense chest pain with marked ST-segment depression in the precordial leads. Acute circumflex artery stent thrombosis was confirmed by repeat angiography ([Video 3](http://jacccr.acc.org/video/2020/20_1411_VID3.mp4){#intref0025}). Optical coherence tomography demonstrated in-stent mixed thrombus with mild proximal stent underexpansion and a nonsignificant dissection of the distal stent edge. Intracoronary tirofiban was effective in reducing thrombus burden, and proximal overexpansion of the stent was performed ([Videos 4](http://jacccr.acc.org/video/2020/20_1411_VID4.mp4){#intref0030} and [5](http://jacccr.acc.org/video/2020/20_1411_VID5.mp4){#intref0035}). The patient received acetyl salicylic acid (ASA), ticagrelor, and a 24-h continuous infusion of tirofiban after the procedure. He had dry cough with a chest radiograph compatible with COVID-19 infection, but no tests were performed because we were at the early stage of the pandemic and the threshold of suspicion was high. The patient was discharged at 4 days. Serological testing 23 days later confirmed that immunoglobulin G was positive for severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2).Figure 1Case 1: Acute Stent Thrombosis**(A)** Electrocardiogram at admission showing lateral ST-segment elevation myocardial infarction. **(B)** Electrocardiogram 30 min after circumflex percutaneous coronary intervention showing posterior ST-segment elevation myocardial infarction. **(C)** Ramus occlusion **(+)** and 2 critical lesions **(asterisks)** in the proximal circumflex artery and first marginal branch. **(D)** Final result after percutaneous coronary intervention of ramus **(arrowhead)** and circumflex arteries (**dotted line** indicates the position of 2 overlapped drug-eluting stents). **(E)** Stent thrombosis, with haziness at the **(a)** proximal and **(d)** distal edge, as well as **(c)** at the bifurcation. **(F)** Final result after stent thrombosis treatment, with complete flow restored. **(a to d),**optical coherence tomography imaging showing **(a)** no compromise of the proximal edge, **(b)** mild proximal underexpansion of stent with mixed thrombus, which can also be observed **(c)** in the origin of the second marginal branch and **(d)** near the distal edge, which has **(e)** mild dissection.

Case 2 {#sec1.2}
------

A 71-year-old man was admitted in 2007 for an inferior STEMI that was treated with right coronary artery DES. He presented with a high-risk non-STEMI resulting from very late right coronary artery stent thrombosis. Thrombectomy, tirofiban, and 2 DESs restored flow. The patient reported fever and cough some days before admission; blood testing and chest radiograph showed COVID-19--compatible findings. The patient remained asymptomatic, and no confirmatory tests were performed for the same reason as in the first patient.

Case 3 {#sec1.3}
------

An 86-year-old man with history of non-STEMI in 2018 that was treated with left anterior descending (LAD) artery DES underwent primary angioplasty for 6 h of chest pain and an anterior STEMI. Very late LAD artery stent thrombosis was found, and a new DES was implanted. The patient was asymptomatic, but because the COVID-19 pandemic had reached its peak, a pre-admission polymerase chain reaction test was performed, with a positive result. The patient had a favorable course and was discharged 5 days later.

Case 4 {#sec1.4}
------

An 85-year old man underwent PCI with ostial LAD artery DES implantation in 2005. He presented at the pandemic peak with chest pain, a left ventricular ejection fraction of 30%, and anterior ST-segment elevation with prior Q waves ([Figures 2A to 2D](#fig2){ref-type="fig"} ). The result of immunoglobulin M serological testing was positive despite the absence of respiratory symptoms. Angiography demonstrated very late LAD artery stent thrombosis ([Video 6](http://jacccr.acc.org/video/2020/20_1411_VID6.mp4){#intref0040}), which was treated with balloon angioplasty, thrombectomy, and tirofiban ([Video 7](http://jacccr.acc.org/video/2020/20_1411_VID7.mp4){#intref0045}). Intravascular ultrasound was performed and showed in-stent thrombus, appropriate stent expansion, and nonsignificant neoatherosclerosis ([Video 8](http://jacccr.acc.org/video/2020/20_1411_VID8.mp4){#intref0050}). The patient was treated with combined lopinavir and ritonavir, and despite his age, received ASA and prasugrel as antiplatelet therapy. Ten days later, prasugrel was replaced by clopidogrel (after antiviral treatment was completed), and the patient was discharged.Figure 2Case 4: Very Late Stent Thrombosis**(A)** Baseline electrocardiogram showing anterior Q waves with negative T waves in the precordial leads. **(B)** Electrocardiogram on admission, with ST-segment elevation in the precordial leads and reciprocal changes in the inferior leads. **(C)** Complete ostial left anterior descending artery stent thrombosis; **(a to d)** indicate the level of the images obtained with intravascular ultrasound. **(D)** Left anterior descending artery flow restored after percutaneous coronary intervention. Intravascular ultrasound images: **(a),** left main coronary artery immediately proximal to stent; **(b)** and **(c),** correct expansion without malapposition or neoatherosclerosis and with thrombus adhered to the stent; **(d),** distal edge of the stent, without complications.

Discussion {#sec2}
==========

The COVID-19 pandemic has significantly decreased worldwide interventional cardiology activity. In Spain, cardiac catheterization procedures have been reduced by 48%, with a reduction of 40% for primary angioplasty ([@bib2]). Similar data have been reported in the United States ([@bib3]). Compared with the immediate period before the pandemic peak (February 1 to 23, 2020), we experienced a 38% decrease in PCIs at our center between March 15, 2020 and April 5, 2020 (31 vs. 50). Moreover, we had an increase in the incidence of stent thrombosis (4 vs. 0; 13% of PCIs performed during this period). In 2019, we performed 899 PCIs, with 11 (1.2%) cases of stent thrombosis. Given the perception of a high rate of stent thrombosis among COVID-19 cases in other centers in Spain, a prospective registry is being conducted.

A greater thrombogenic predisposition, both arterial and venous, during COVID-19 has been established. Pathophysiologically, the cytokine storm that occurs 5 to 7 days after the onset of symptoms promotes the coagulation cascade, as well as platelet activation mediated by interleukin-6 and tissue factor. The latter induces an increase in thrombin and fibrin synthesis, as well as platelet production. Thrombocytosis can occur, as can high levels of D-dimer and fibrinogen, with intravascular disseminated coagulation criteria often fulfilled ([@bib4],[@bib5]). Additionally, endothelial damage, which could be caused by the virus binding to the angiotensin-converting enzyme receptor and the stasis promoted by the permanent inflammation, would complete the Virchow triad criteria ([@bib6]).

We present 1 case of acute stent thrombosis and 3 very late stent thrombosis cases ([Table 1](#tbl1){ref-type="table"} ). Despite no initial COVID-19 testing in 2 cases, symptoms and subsequent testing ([Figures 3A to 3D](#fig3){ref-type="fig"} ) supported that the patients were infected at the time of stent thrombosis ([Table 2](#tbl2){ref-type="table"} ).Table 1Summary of Cases of Stent Thrombosis Presented During the COVID-19 PandemicCase 1Case 2Case 3Case 4Age, yrs49718685SexMaleMaleMaleMaleCOVID-19 statusIgG +SuspicionPCR +IgM +COVID-19 presentationCough, bilateral ground-glass infiltratesCough, fever, bilateral ground-glass infiltratesAsymptomatic, bilateral ground-glass infiltratesAsymptomatic, bilateral ground-glass infiltrates.COVID19 treatmentNoNoHydroxychloroquine\
AcetylcysteineHydroxychloroquine\
Azithromycin\
Lopinavir-ritonavir\
CeftriaxonePresentationSTEMINSTEMISTEMISTEMIPhysical examinationRales up to ½ lung fieldsNormalNormalPeripheral edema Heart rate (beats/min)110537580 Blood pressure (mm Hg)150/86150/85160/80110/60 S[o]{.smallcaps}~2~ (%)90969595 Temperature (ºC)36.537.53635.6Vessel responsibleProximal circumflex -- OM (90% stenosis)Mid-RCA (occluded)Proximal LAD (occluded)Proximal LAD (occluded)Stent thrombosedDES ×2 (Ultimaster 3 × 15 mm)BMS (Driver 3.5 × 18 mm)DES (Cypher 3 × 18 mm)DES (Synergy 3.5 × 32 mm)TimingAcute (30 min)Very late (13 yrs)Very late (2 yrs)Very late (4 yrs)APT before admissionNoneASAASAASAAPT during PCIASA + clopidogrelASA+ clopidogrelASA + clopidogrelASA+ prasugrelAnticoagulation during PCIUFH 8,000 IUUFH 5,000 IUUFH 8,000 IUUFH 7,000 IUVascular approachRight radialLeft radialLeft radialLeft radialPCI techniqueGPI\
BA\
OCT guidanceThrombectomy\
DES (Synergy 4 × 28 mm)\
GPIDES (Ultimaster 3 × 15 mm)Thrombectomy\
BA\
IVUS guidanceAPT dischargeASA + ticagrelorASA+ ticagrelorASA + clopidogrelASA + clopidogrelLVEF (%) at discharge45%55%45%30%Risk factors for stent thrombosis PatientDM\
LVD\
ACSCKD\
ACSAge\
DM\
LVD\
CKD\
ACS\
PADAge\
LVD\
ACS LesionBifurcationNoNoOstial lesion ProceduralPrimary PCI\
Multivessel PCI\
Malapposition\
Underexpansion\
DissectionNoFirst-generation DES\
Overlapped stentsLong stent[^1]Figure 3Chest Radiographs of Patients**(A)** Case 1, peripheral interstitial infiltrates, mainly affecting the left base and subpleural regions. **(B)** Case 2, both central and peripheral alveolointerstitial infiltrates, probably from mixed heart failure. **(C)** (Case 3) and **(D)** (Case 4), mild infiltrates, mainly central and resulting from mild heart failure. D = right; PA = posteroanterior.Table 2Summary of Laboratory TestingCase 1Case 2Case 3Case 4COVID-19 testsIgM−/IgG +Not performedPCR +IgM+/IgG−D-dimer (45--500 μg/l)6305396621,251Fibrinogen (150--450 mg/dl)443271263263Partial thromboplastin time (25--39 seg)32.728.329.431.1Prothrombin time (70%--120%)67939355Platelets (140--400 × 10^3^/μl)175127167165C-reactive protein (0--5 mg/l)12249.640.5Ferritin (30--400 ng/ml)1,2331,010722,411Lymphocyte count (1--4 × 10^3^/μl)1,5909302,240790High-sensitivity T troponin peak (0--14 pg/ml)2,4043,3242,4067,782Creatine kinase peak (38--174 U/l)8746345231,276GFRe (ml/min)110566844[^2]

Very late stent thrombosis with a first-generation DES occurs in the presence of a sustained inflammatory response. Other factors such as delayed endothelialization, late malapposition, or neoatherosclerosis plaque rupture can sometimes be implicated ([@bib7]). Two of our patients had chronic kidney disease, which can induce a permanent inflammatory response, and 1 patient had a first-generation DES. The patient with acute stent thrombosis had mild proximal stent underexpansion detected by optical coherence tomography. All patients were receiving appropriate antiplatelet therapy at the time of stent thrombosis; the patient with acute thrombosis was following an ASA-clopidogrel regimen, whereas the 3 patients with very late stent thrombosis were taking ASA therapy. We think that SARS-CoV-2 infection triggered stent thrombosis in these patients.

Finally, the latest official statements for COVID-19 patients recommend following current PCI guidelines ([@bib8]). Expert recommendations have been published on antithrombotic therapy management, with special consideration given to possible interactions with the drugs used for COVID-19 ([@bib9]). This is especially important with drugs metabolized through CYP3A4, such as clopidogrel or ticagrelor, which could interact with antiviral agents such as lopinavir combined with ritonavir or darunavir combined with cobicistat. Therefore, prasugrel could be the drug of choice in patients without contraindications (prior stroke) but who are \>75 years of age or have a weight \<60 kg if antiviral agents are considered indispensable. Because of the low evidence on the effectiveness of these antiviral agents against SARS-CoV-2, antiplatelet therapy should be prioritized for COVID-19 patients in the setting of acute coronary syndromes.

Appendix {#appsec1}
========

[Online Video 1](http://jacccr.acc.org/video/2020/20_1411_VID1.mp4){#intref0055}Case 1: Midocclusion of the Ramus ArteryThe ramus artery occlusion was the index lesion. Critical stenoses in circumflex artery is also present. [Online Video 2](http://jacccr.acc.org/video/2020/20_1411_VID2.mp4){#intref0060}Case 1: Final Result After Percutaneous Coronary Intervention of the Circumflex and Ramus Arteries [Online Video 3](http://jacccr.acc.org/video/2020/20_1411_VID3.mp4){#intref0065}Case 1: Angiogram of the Stent ThrombosisNo occlusive thrombosis was present, but haziness is seen proximal to the edges of the stent. Haziness is also seen at the bifurcation with the second marginal branch, with distal occlusion of this branch. [Online Video 4](http://jacccr.acc.org/video/2020/20_1411_VID4.mp4){#intref0070}Case 1: Optical Coherence Tomography of the Stent ThrombosisMixed thrombus is seen mainly at the proximal segment, with mild underexpansion. Thrombus at the origin of the bifurcation with second marginal branch, mild dissection (\<60º and \< 2 mm length) at distal edge. [Online Video 5](http://jacccr.acc.org/video/2020/20_1411_VID5.mp4){#intref0075}Case 1: Angiogram Showing Final Result After Glycoprotein IIb-IIIa Inhibitor Use and Overexpansion of the Proximal Segment of the Stent [Online Video 6](http://jacccr.acc.org/video/2020/20_1411_VID6.mp4){#intref0080}Case 4: Angiogram Showing Occlusive Ostial Left Anterior Descending Artery Stent Thrombosis [Online Video 7](http://jacccr.acc.org/video/2020/20_1411_VID7.mp4){#intref0085}Case 4: Angiogram Showing Final Thrombolysis In Myocardial Infarction III Flow Result After Glycoprotein IIb-IIIa Inhibitor Use, Thrombectomy, and Balloon Angioplasty of the Left Anterior Descending Artery Thrombosis [Online Video 8](http://jacccr.acc.org/video/2020/20_1411_VID8.mp4){#intref0090}Case 4: Intravascular ultrasound Showing In-stent Fresh Thrombus With Correct Expansion and No or Mild NeoatherosclerosisProximal and distal edges are not damaged.
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Appendix

For supplemental videos, please see the online version of this paper.

[^1]: ACS = acute coronary syndrome; APT = antiplatelet therapy; ASA = acetyl salicylic acid; BA = balloon angioplasty; BMS = bare metal stent; CKD = chronic kidney disease; COVID-19 = coronavirus disease-2019; DES = drug-eluting stent; DM = diabetes mellitus; GPI = glycoprotein IIb-IIIa inhibitor; IU = international units; IVUS = intravascular ultrasound; NSTEMI = non--ST-segment elevation myocardial infarction; OCT = optical coherence tomography; OM = obtuse marginal branch; RCA = right coronary artery; LAD = left anterior descending; LVEF = left ventricular ejection fraction; LVD = left ventricular dysfunction; PAD = peripheral artery disease; PCI = percutaneous coronary intervention; S[o]{.smallcaps}~2~ = oxygen saturation; STEMI = ST-segment elevation myocardial infarction; UFH = unfractionated heparin.

[^2]: COVID-19 = coronavirus disease-2019; GFRe = estimated glomerular filtration rate; IgG = immunoglobulin G; IgM = immunoglobulin M; PCR = polymerase chain reaction; seg = segmented.
